Japan Sets Policy To Encourage Bioventures To Develop Orphan Drugs
This article was originally published in PharmAsia News
Executive SummaryJapan is set to undertake a national policy to lead bioventures into developing orphan drugs in the country
You may also be interested in...
CES 2020: Panel Discusses Health Care In 2040 – Empowered Consumer, Digital Transformation, Data Sharing, Open Source
AveXis President David Lennon talked to Pink Sheet about quality enhancement at the gene therapy unit, a clinical trial hold for Zolgensma in Type 2 SMA, and expansion in gene therapy.
With business heavily dependent on sales revenue from Medicare Part D and other US government programs, Lilly will be expected to narrow the gap between US prescription and sales growth.